Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Calliditas Therapeutics AB announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for patent application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer”.

Scroll to Top